Exebacase cf-301

Author: fyes

August undefined, 2024

WebMay 14, 2024 · Lysin exebacase (CF-301) is an anti-staphylococcal lysin with potent bactericidal activity against S. aureus and additionally against coagulase-negative … WebDec 1, 2024 · Exebacase (lysin CF-301) is a potent antistaphylococcal lysin, with distinguishing features that include a low propensity for resistance, synergy with conventional antibiotics, activity against antibiotic-resistant strains, an extended post-antibiotic effect and, importantly, potent activity against biofilm bacteria ( Schuch et al., …

Contrafect And Its Narrowed Phase 3 Approach (NASDAQ:CFRX)

WebAug 28, 2024 · Presentation Title: Development of Exebacase (Lysin CF-301), a Direct Lytic Agent with Potent Activity Against Staphylococcus aureus Speaker: Cara Cassino, M.D., Chief Medical Officer and Executive Vice President of Research and Development Session: The Road from Pre-Clinical to Clinical for Non-Traditional Therapies WebDec 1, 2024 · Exebacase (lysin CF-301) is a potent antistaphylococcal lysin, with distinguishing features that include a low propensity for resistance, synergy with … dwight rhoden complexions

ContraFect Announces Presentation of New Data from its

WebOct 26, 2024 · Exebacase has been granted Breakthrough Therapy designation for the treatment of MRSA bloodstream infections by the U.S. Food and Drug Administration (FDA). The Company is providing expanded access to exebacase under a treatment protocol available to clinical sites participating in the ongoing Phase 3 study, which enables … WebFeb 10, 2024 · CF-301, also known as Exebacase is ContraFect's lead program. CF-301 was discovered in the laboratory of Dr. Vincent Fischetti and has been licensed from Rockefeller University. Lysins are ... WebNov 18, 2024 · On October 2, 2024, ContraFect Corp. (NASDAQ:CFRX) announced that following a successful ‘end-of-Phase 2’ meeting with the FDA the company is planning to … dwight rich middle school

Direct Lysis of Staph Aureus Resistant Pathogen Trial of …

ContraFect Announces First Gram-negative Product Candidate

WebApr 28, 2024 · Exebacase (CF-301), a novel, anti-staphylococcal lysin (cell-wall hydrolase) is the first agent of this class to enter late-stage clinical development (Phase 3, NCT04160468) for the treatment of ... WebJun 18, 2024 · Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis.A multilaboratory Clinical and Laboratory Standards Institute (CLSI) M23-defined tier 2 … crystal kitchen cabinet door knobs interiorWebJan 6, 2024 · About Exebacase (CF-301): Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of... crystal kitchen lexington va menu

"WebMay 23, 2024 · CF-301 is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics. ... Bressler A, Evans D, Moran GJ, Rupp ME, Wise R, Corey GR, Zervos M, Douglas PS, Cassino C. Exebacase … " - Exebacase cf-301

Exebacase cf-301

The Anti-Staphylococcal Lysin, CF-301, Activates Key Host …

WebMar 2, 2024 · CF-301 (exebacase) is a recombinantly produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class to enter clinical development in the United States for ... WebDec 18, 2024 · We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase (CF-301), which is the first lysin to ...

Did you know?

WebFeb 17, 2024 · Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including …

WebJan 25, 2024 · Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of ... WebMay 14, 2024 · Frontiers Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection ORIGINAL RESEARCH article Front. Med., 14 May 2024

WebExebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for … Our lead lysin, exebacase (CF-301) is an investigational product candidate that … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Exebacase (CF-301) Exebacase is a novel, investigational lysin with potent activity … Gary Woodnutt, Ph.D. Senior Vice President of Translational Sciences and … Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus … Roger J. Pomerantz, M.D., F.A.C.P. President, Chief Executive Officer and … About Contrafect Corporation. We are focused on developing first-in-class … Overview. Our therapeutic product candidates are direct lytic agents (DLAs) … Company Overview. ContraFect is a clinical-stage biotechnology company … Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US. Telephone: 914 … WebDec 20, 2024 · About Exebacase (CF-301): Exebacase is an anti-staphylococcal recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream infections (BSIs) also known as bacteremia. It is the first lysin to enter clinical studies in the U.S. and was granted …

WebJan 7, 2024 · Exebacase (CF-301) is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of blood …

WebMar 3, 2024 · “Lysin exebacase (CF-301) exhibits potent bactericidal activity in human synovial fluid (HSF) against biofilm-forming Staphylococcus epidermidis (S. epidermidis) isolates.” in European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). April 13–16; Amsterdam, Netherlands. Google Scholar. crystal kitchen door handlesWebJun 17, 2024 · About Exebacase (CF-301): Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus , a … dwight richmond obituary cinn ohioWebContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients 26 oct. 2024 07h00 HE Source: ContraFect Corporation YONKERS, N.Y., Oct. 26, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the … dwight richmond town and country marketsWebAug 5, 2024 · Exebacase . Exebacase is under investigation in clinical trial NCT03163446 (Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial … crystal kitchen cabinet reviewsWebContraFect’s Exebacase (CF-301) Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study. 07 janv. 2024 07h00 HE Source: ContraFect Corporation Proof of concept that new class of lysin biologics has the ... dwight rickard florence alWebOct 4, 2024 · About Exebacase (CF-301): Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus, a major cause of bloodstream... crystal kitchen island pendantsWebLysin CF-301 is being developed to treat Staphylococcus aureus because of its potent, specific, and rapid bacteriolytic effects. It also demonstrates activity on drug-resistant … dwight rich school lansing mi